Warnings
MDMA Pill, Ecstasy
Očekivano MDMA. Otkriveno MDMA, Caffeine, Paracetamol. Lokacija: Hackney, Haringey, Islington (N15), England. Datum: 2026-06-16. Izvor: wedinos.wales.
Appearance
- Logo: MDMA Pill, Ecstasy
- Color: green, pink
- Media: 1 sample photo
Detected Substances
- MDMA
- Caffeine
- Paracetamol
Expected vs Detected
MDMA
Detected result: MDMA, Caffeine, Paracetamol
Sample Details
No additional sample descriptors available.
Testing Context
- Location: Hackney, Haringey, Islington (N15), England
- Date tested: 2026-06-16
- Source: wedinos.wales
Harm Reduction
- Similar-looking pills can contain different substances or strengths.
- Use drug checking services when available.
- Start low and avoid assuming a logo identifies the contents.
SampleDNA Beta
4100 povezanih upozorenja · Saznajte više o uobičajenim nečistoćama.
- MDMAOtkriveno
- CaffeineOtkriveno
- ParacetamolOtkriveno
Povezani uzorci i kombinacije
Ecstasy logo
Isti logo se pojavljuje u povezanim rezultatima testiranja droga.
Caffeine + MDMA
Otkriveno zajedno u povezanim rezultatima kontrole supstanci.
Amphetamine + Caffeine + Ketamine + MDMA
Otkriveno zajedno u povezanim rezultatima kontrole supstanci.
6-MAM + Acetylcodeine + Caffeine + Heroin + Noscapine + Papaverine + Paracetamol
Otkriveno zajedno u povezanim rezultatima kontrole supstanci.
- Acetylcodeine + Caffeine + Heroin + 6-MAM + Noscapine + Papaverine + Paracetamol
- Acetylcodeine + Caffeine + Heroin + 6-MAM + Noscapine + Paracetamol + Papaverine
- 6-MAM + Noscapine + Papaverine + Acetylcodeine + Caffeine + Heroin + Paracetamol
- Acetylcodeine + Caffeine + Heroin + 6-MAM + Noscapine + Paracetamol + Papaverine
- Heroin + 6-MAM + Noscapine + Paracetamol + Acetylcodeine + Caffeine + Papaverine
- Acetylcodeine + Heroin + 6-MAM + Noscapine + Caffeine + Papaverine + Paracetamol
Acetylcodeine + Caffeine + Heroin + Noscapine + Papaverine + Paracetamol
Otkriveno zajedno u povezanim rezultatima kontrole supstanci.
Links
This static page is intended as the readable export baseline for crawler and low-capability delivery.
